GlaxoSmithKline in Talks to Acquire Nuvalent for Over $9 Billion

According to Financial Times, GlaxoSmithKline is in negotiations to acquire Nuvalent, a biotechnology company, for over $9 billion.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments